APhase I Study of OncoVEX, a Second-Generation Oncolytic Herpes SimplexVirus Expressing Granulocyte Macrophage Colony-Stimulating Factor

J. Hu,R. Coffin,C. Davis,N. Graham,N. Groves,P. Guest,K. Harrington,N. James,C. Love,I. McNeish,L. Medley,AgnieszkaMichael,C. Nutting,H. Pandha,C. Shorrock

Abstract:Purpose:To conduct a phase I clinical trial with a second-generation oncolytic herpes simplex virus (HSV) expressing granulocyte macrophage colony-stimulating factor (OncoVEX) to determine the safety profile of the virus, look for evidence of biological activity, and identify a dosing schedule for later studies. Experimental Design: The virus was administered by intratumoral injection in patients with cutaneous or s.c. deposits of breast, head and neck and gastrointestinal cancers, and malignant melanoma who had failed prior therapy. Thirteen patients were in a single-dose group, where doses of 10, 10, and 10 plaque-forming units (pfu)/mL were tested, and 17 patients were in a multidose group testing a number of dose regimens. Results: The virus was generally well tolerated with local inflammation, erythema, and febrile responses being the main side effects. The local reaction to injection was dose limiting in HSVseronegative patients at 10 pfu/mL. The multidosing phase thus tested seroconverting HSVseronegative patients with 10 pfu/mL followed by multiple higher doses (up to 10 pfu/mL), which was well tolerated by all patients. Biological activity (virus replication, local reactions, granulocyte macrophage colony-stimulating factor expression, and HSV antigen-associated tumor necrosis), was observed. The duration of local reactions and virus replication suggested that dosing every 2 to 3 weeks was appropriate. Nineteen of 26 patient posttreatment biopsies contained residual tumor of which 14 showed tumor necrosis, which in some cases was extensive, or apoptosis. In all cases, areas of necrosis also strongly stained for HSV. The overall responses to treatment were that three patients had stable disease, six patients had tumors flattened (injected and/or uninjected lesions), and four patients showed inflammation of uninjected as well as the injected tumor, which, in nearly all cases, became inflamed. Conclusions: OncoVEX is well tolerated and can be safely administered using the multidosing protocol described. Evidence of an antitumor effect was seen. Oncolytic virus therapy is a promising approach to cancer treatment, particularly for the locoregional control of solid tumors. Here, viruses that selectively replicate in tumor compared with normal cells are used such that tumor cells are killed by lytic virus replication and normal cells are spared. Various viruses have been tested for use as oncolytic agents, including adenovirus, Newcastle disease virus, and vesticular stomatitis virus with promising preclinical, and, in some cases, clinical results. However, although safety has been shown, it is evident that improvements to oncolytic potency would be beneficial. Herpes simplex virus (HSV) is a highly lytic virus in which deletion of the extensively studied gene encoding ICP34.5 provides tumor selectivity (see below). ICP34.5-deleted HSV infects and replicates in a broad range of human tumor cells, apparently irrespective of the genetic aberration resulting in their transformation. HSV thus has the potential to be a useful oncolytic virus that could be used in the treatment of a broad spectrum of solid tumor types. Thus far, oncolytic HSVs have been tested in several clinical trials with encouraging results. These viruses are all deleted for one or both copies of ICP34.5 (virus strains 1716 and NV1020; refs. 1–3), or ICP34.5 and ICP6 (virus strain G207; refs. 4, 5). Cancer Therapy: Clinical Authors’Affiliations: Department of CancerMedicine, Imperial College Schoolof Medicine; RoyalMarsdenHospital; Department of Oncology, St GeorgesHospital Medical School; University College London, London, United Kingdom; Biovex, Inc., Cambridge, Massachusetts; Institute for Cancer Studies,The University of Birmingham, Birmingham, United Kingdom; and Oxford Therapeutics Consulting, TheMagdalen Centre, Oxford, United Kingdom Received 3/28/06; revised 6/1/06; accepted 6/22/06. Grant support: Biovex, Inc. The costs of publication of this article were defrayed in part by the payment of page charges.This article must therefore be hereby marked advertisement in accordance with18 U.S.C. Section1734 solely to indicate this fact. Requests for reprints: Robert S. Coffin, Biovex, Inc., 34 Commerce Way, Woburn, MA 018010. E-mail: rcoffin@biovex.com. F2006 American Association for Cancer Research. doi:10.1158/1078-0432.CCR-06-0759 www.aacrjournals.org Clin Cancer Res 2006;12(22) November15, 2006 6737 Research. on January 8, 2018. © 2006 American Association for Cancer clincancerres.aacrjournals.org Downloaded from 1716 and G207 have been tested in clinical trials in glioma, with some evidence of disease stabilization (6–8), and NV1020 has been tested followed by chemotherapy in 12 patients with colorectal cancer hepatic metastases with some minor responses (9). 1716 has also been tested in melanoma at very low dose (10). All the patients in these clinical trials tolerated the treatment well. Thus, safety of ICP34.5-deleted HSV has been shown in multiple clinical studies. However, although suggestions of efficacy have been obtained, greater potency viruses would likely improve the effectiveness of the treatment seen. Therefore, we set out to build on this previous work to develop a higher-potency oncolytic HSV while retaining the safety profile of these previous viruses. This virus was also developed to induce a more potent antitumor immune response through the deletion of the HSV gene encoding ICP47, which blocks antigen presentation in HSV-infected cells (11) and the delivery of the gene encoding human granulocyte macrophage colony-stimulating factor (GM-CSF). Improved oncolysis was achieved through the use of a more potent clinical isolate of HSV for construction of the virus, and, in addition to the deletion of ICP34.5, which is well documented to provide tumor-selective virus replication (12–16), the expression of the US11 gene as an immediate early rather than late gene that has previously been shown to boost tumor-selective virus replication (11, 17, 18). GM-CSF was chosen as it induces myeloid precursor cells to proliferate and differentiate, is a recruiter and stimulator of dendritic cells, has given promising preclinical and clinical results (19–23), and is used routinely in clinical practice. In addition, autologous tumor cell vaccines expressing GM-CSF have shown significant clinical benefit (24, 25). This virus (OncoVEX), and the other viruses constructed during the development of OncoVEX, have been tested in extensive preclinical studies showing significant antitumor effects. These include that both the use of a clinical isolate for virus construction and the increased expression of US11 greatly increase oncolytic potency and that expression of GM-CSF greatly improves the effects seen in tumors that have not themselves been subjected to virus injection (26). Table 1. Patient characteristics and responses Patient Dose (pfu/mL) Age/sex HSV sero status Pathology Prior therapy Diag 101 10 50/F Positive Breast S, CXT, RXT 102 10 74/F Negative Breast H, S, CXT 103 10 55/F Positive Breast CXT, S, RXT 104 10 70/F Positive Colorectal S, CXT 201 10 80/F Positive Melanoma S, CXT, laser, thalidomide 202 10 57/F Negative Breast S, CXT, RXT, TNF Autovac trial 203 10 40/F Negative Breast CXT, S 204 10 59/F Positive Breast S, H, CXT 205 10 31/F Negative Melanoma S, CXT, I, TAM Glivec, thalidomide 301 10 30/M Positive Melanoma S, CXT, RXT, I, isolated limb perfusion, thalidomide 302 10 61/F Positive Breast S, CXT, TAM, H, RXT 303 10 63/F Positive Breast TAM, H, CXT, RXT 304 10 67/F Positive Breast S, TAM, H, RXT 401 10, 10, 10 39/F Negative Breast S, high-dose CXT with stem cell transplant, CXT, RXT 402 10, 10, 10 61/F Negative Head and neck S, RXT 403 10, 10, 10 60/F Negative Breast TAM, CXT, RXT 601 10, 10, 10 48/M Negative Colorectal CXT, S 602 10, 10, 10 47/F Negative Breast S, H, TAM, CXT, RXT 603 10, 10, 10 43/F Negative Breast CXT, herceptin 604 10, 10, 10 45/F Negative Melanoma S, dendritic cell trial 501 10, 10, 10 50/F Positive Melanoma S, CXT, I, laser 502 10, 10, 10 59/F Positive Melanoma S 503 10, 10, 10 62/M Positive Melanoma CXT, RXT, I, S 701 10, 10, 10 55/F Positive Head and neck S, CXT, RXT 702 10, 10, 10 57/F Positive Head and neck S, CXT, RXT 703 10, 10, 10 50/M Positive Head and neck CXT, RXT, S 704 10, 10, 10 53/M Positive Head and neck S, CXT, RXT 705 10, 10, 10 49/M Positive Melanoma S, CXT, RXT 706 10, 10, 10 56/M Positive Melanoma S 707 10, 10, 10 80/F Positive Breast S, TAM, H, CXT NOTE: Patients had progressive disease unless otherwise noted. Abbreviations: S, surgery; H, hormonal therapy; I, immunotherapy; TAM, tamoxifen; CXT, chemotherapy; RXT, radiotherapy; U, injected and/ or uninjected lesion(s) ulcerated; V, vesicles; E, erythmatous/inflamed (degree: +, ++, +++); FI, flattening/shrinkage of injected lesion; FU, flattening/shrinkage of uninjected lesion(s); SD, stable disease; EU, uninjected lesion inflamed (degree: +, ++, +++); N, necrosis in tumor biopsy; A, apoptosis in tumor; H, HSV antigen detected in necrotic areas; P, pain in injected or uninjected lesion(s). *Small biopsy, possibly not representative. cPatient 401 also received three further doses over 7 weeks on a compassionate basis. Cancer Therapy: Clinical www.aacrjournals.org Clin Cancer Res 2006;12(22) November15, 2006 6738 Research. on January 8, 2018. © 2006 American Association for Cancer clincancerres.aacrjournals.org Downloaded from Materials andMethods OncoVEX. OncoVEX has been described previously (26). Briefly, the virus is based on HSV-1 strain JS-1 in which the genes encoding ICP34.5 and ICP47 have been completely deleted. Deletion of ICP47 also results in the US11 gene being under the control of the ICP47 immediate early promoter, rather than the US11 late promoter that results in enhanced tumor-selective replication (26). The ICP34.5-encoding sequences have been replaced with a cassette consisting of the cytomegalovirus promoter, the